Hans Hillege is Professor in Cardiology and member of the Committee for Medicinal Products for Human Use (CHMP) for the Netherlands. The CHMP of the European Medicines Agency (EMA) is responsible for preparing the Agency's opinions on applications submitted for marketing authorisation and on all questions concerning medicinal products for human use. His educational record includes a Bachelor’s degree in Physical Education, Master’s degrees in Medicine and Epidemiology and a PhD from the University of Groningen. His fields of specialization and research include cardiovascular epidemiology and the impact of extracardiac comorbidities with specific interest in the coexistence of cardiovascular and kidney disease, epidemiological models, clinical trials, evidence based medicine, medical decision-making and health information technology. From 1994 to 1998 he was project leader coronary and endovascular stents and Director Endovascular at Cordis Europe NV, a Johnson and Johnson Company. In 1998 he became a university teacher of the Department of Clinical Pharmacology at the University of Groningen and Clinical Assessor for the Medicines Evaluation Board, The Netherlands. In 1998 he became a clinical expert for the European Agency for the Evaluation of Medicinal Products (EMEA) and Member of the Efficacy Working Party. Between 2001 and 2013 he was director of the Trial Coordination Center at the University Hospital Groningen, in 2008 he was appointed Professor Cardiology and in 2013 he became CHMP member. He was one of the founders of the of the LifeLines project, and coordinated several national and international research projects. He was member in several steering committee’s related to clinical trials and is involved on a managerial and scientific level in a number of large scaled cohort studies. He has supervised more than 25 PhD projects (8 currently running) and authored/co-authored more than 300 scientific publications and book chapters.
|Last modified:||05 July 2017 10.02 a.m.|